VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

Conference call to take place Friday, February 21, 2019 at 8:30 am Eastern time

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2019.

Event: VolitionRx Limited Fourth Quarter & Full Year 2019 Earnings and Business Update Conference CallDate: Friday, February 21, 2020Time: 8:30 a.m. Eastern timeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/International: 1-201-493-6779Conference ID: 13699351

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition's activities, including details of new and ongoing clinical trials, important events which have taken place in 2019, and milestones for 2020 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until March 6, 2020. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13699351.

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics(TM) is a trademark of Volition and its subsidiaries.

For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:

Twitter: https://twitter.com/volitionrx LinkedIn: https://www.linkedin.com/company/volitionrx Facebook: https://www.facebook.com/VolitionRx/ YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition

mediarelations@volition.com

+44 (0)7557 774620

Scott Powell, Volition

investorrelations@volition.com

+1 (646) 650 1351

Joseph Green, Edison Advisors

jgreen@edisongroup.com

+1 (646) 653 7030

View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-year-2019-earnings-conference-call-and-business-update-301006813.html

SOURCE VolitionRx Ltd

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus